
Building A New Antibody Discovery Platform With Infinimmune's Wyatt McDonnell, Ph.D.
Episode 305
We love to hear from our listeners. Send us a message. On this week's episode of the Business of Biotech, Wyatt McDonnell, Ph.D., cofounder and CEO at Infinimmune, talks about how single-cell biology and computational rigor led to the formation of Infinimmune, and a new way to discover human-derived antibody drugs. Wyatt explains Infinimmune's 'discovered in humans' antibody discovery platform, how the company was launched and initially funded, and how Infinimmune landed a Merck collaboration worth up to $838 million. Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter. Get in touch with guest and topic suggestions: ben.comer@lifescienceleader.com Find Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/
Publisher
Business Of Biotech
Published
May 11, 2026
Duration
54 min
Format
Podcast
Category
Issues · Business
Source
RSS feed
Host
Ben Comer
Business Of Biotech
@businessofbiotech
#building #antibodydiscoveryplatform #infinimmuneswyattmcdonnell #management #lifesciences
